Evogene (EVGN) Q3 2025 earnings summary

Executive summary

• Advanced strategic transition to focus on computational chemistry and generative AI for small molecule design in pharma and agriculture, with Campus AI as the core technology engine.

• Completed major organizational change and cost reduction plan, resulting in a leaner, more focused company.

• Sale of Lavie Bio's activities and Microboost AI for Ag to ICL generated $7.9 million in Q3 2025, strengthening the balance sheet.

• Integrated AgPlenus more deeply into core operations and scaled down Biomica and Canonic activities.

• Strategic collaborations in ag-chemicals (Bayer, Corteva) and new pharma partnerships underway.

Financial highlights

• Q3 2025 operating expenses net: $2.9 million, down from $6.6 million in Q3 2024.

• Revenues for nine months ended September 30, 2025: $3.5 million, down from $4 million year-over-year, mainly due to lower AgPlenus revenue and the absence of a one-time Bayer payment.

• Operating loss for nine months: $8.8 million, improved from $15.3 million year-over-year.

• Net income for Q3 2025: $5.2 million, compared to net loss of $8.2 million in Q3 2024, mainly due to gains from discontinued operations.

• Cash and short-term deposits at Q3 end: $16 million, reflecting proceeds from asset sales.

Outlook and guidance

• Expectation to maintain reduced expense levels going forward.

• Anticipate new pharma and ag-chem collaboration agreements in early 2026, with focus on expanding Campus AI partnerships.

• Focused on leveraging ChemPass AI for innovation in pharma and agriculture, with Casterra expected to generate future value.

• Ongoing efforts to strengthen position in Brazil's castor farming and expand Casterra's commercial opportunities.

• Forward-looking statements highlight potential risks from geopolitical instability and reliance on third-party partners.